1. Yu H, Robertson ES. Epstein–Barr Virus History and Pathogenesis. Viruses. 2023; 15(3):714.
2. de Martel C, Ferlay J, Franceschi S ve ark. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol 2012;13: 607–15
3. Hong T, Parameswaran S, Donmez OA ve ark. Epstein-Barr virus nuclear antigen 2 extensively rewires the human chromatin landscape at autoimmune risk loci. Genome Res 2021: 31;
2185–98.
4. Herpesviruses. In: Ryan KJ. eds. Sherris & Ryan’s Medical Microbiology, 8th Edition. McGraw-Hill Education; 2022. Accessed January 17, 2024. https://accessmedicine.mhmedical.com/
content.aspx?bookid=3107&sectionid=260924395
5. Herpesviruses, Poxviruses, & Human Papilloma Virus. In: Chin-Hong P, Joyce EA, Karandikar M, Matloubian M, Rubio L, Schwartz BS, Levinson W. eds. Levinson’s Review of Medical
Microbiology & Immunology, A Guide to Clinical Infectious Diseases, 18th Edition. McGraw Hill; 2024. Accessed January 17, 2024. 2024. https://accessmedicine.mhmedical.com/content.
aspx?bookid=3428&sectionid=284622916
6. Epstein-Barr virus. In Javetz, Melnick & Adelberg’s Medical Microbiology 27th ed. Ed: Carroll KC, Butel JS, Morse SA, Mietzner T. Mc GrawHill Lange, USA 2016, 474-7.
7. Santpere G, Darre F, Blanco S ve ark. Genome-wide analysis of wild-type Epstein-Barr virus genomes derived from healthy individuals of the 1,000 Genomes Project. Genome Biol Evol
2014;6(4):846-60.
8. Bouvard V, Baan R, Straif K ve ark. A review of human carcinogens – part B: biological agents. Lancet Oncol 2009; 10(4):321–2.
9. Bu G-L, Xie C, Kang Y-F ve ark. How EBV Infects: The Tropism and Underlying Molecular Mechanism for Viral Infection. Viruses 2022; 14(11):2372.
10. Moehl BS, Chen J, Sathiyamoorthy K ve ark. Structural and Mechanistic Insights into the Tropism of Epstein-Barr Virus. Mol. Cells 2016, 39, 286–91.
11. Ogembo JG, Kanjıan L, Chiran I ve ark. Human complement receptor typel/CD35 receptor is an Epstein-Barr virüs receptor. Cel Rep 2013; 3:371-85.
12. Frappier, L. (2015). EBNA1. In: Ed. Münz C. Epstein Barr Virus Volume 2. Current Topics in Microbiology and Immunology, Springer, 391: 3-34.
13. Chen D, Yen-Liebermann B. Epstein-Barr virus. Ed: Loeffelholz M, Hodlinka RL, Pinsky BA, Young SA. Clinical Virology Manual 5 th ed, American Society for Microbiology (ASM) Press
Washington DC, 2016: 387-98.
14. Yakovleva LS, Senyuta NB, Goncharova EV ve ark. Epstein-Barr Virus LMP1 oncogene variants in cell lines of different origin]. Mol Biol (Mosk) 2015:49(5):800–10.
15. Tzellos S, Farrell PJ. Epstein-Barr virus sequence variation-biology and disease. Pathogens 2012: 1(2):156–74.
16. Saechan V, Settheetham-Ishida W, Kimura R ve ark. Epstein-Barr virus strains defined by the latent membrane protein 1 sequence characterize Thai ethnic groups. J Gen Virol 2010;
91(8):2054–61.
17. Walling DM, Brown AL, Etienne W ve ark Multiple Epstein-Barr virus infections in healthy individuals. J Virol 2003:77(11):6546–50.
18. Cui X, Snapper CM. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases. Front Immunol. 2021: 8(12):734471.
19. Gore M, Hutt-Fletcher LM. The BDLF2 protein of Epstein-Barr virus is a type II glycosylated envelope protein whose processing is dependent on coexpression with the BMRF2 protein. Vi-
rology 2009;383:162–7.
20. Valencia SM, Hutt-Fletcher LM. Important but differential roles for actin in trafficking of Epstein-Barr Virus in B cells and epithelial cells. J Virology 2012; 86:2-10.
21. Kempkes B, Robertson ES. Epstein-Barr virus latency: current and future perspectives. Curr Opin Virol. 2015;14:138-44.
22. Johannsen EC, Kaye KM. Epstein-Barr Virus (Infectious Mononucleosis, Epstein-Barr Virus–Associated Malignant Diseases, and Other Diseases) Mandell, Douglas, and Bennett’s Principles
and Practice of Infectious Diseases. Ed: Bennett JE, Dolin R, Blaser MJ. 8th Edition, Elsevier Saunders, 2015: 1754-71.
23. Aydemir Ş, Erensoy S. Epstein-Barr virüsün seroprevalansı: bir alan çalışması. İnfeksiyon Dergisi 1999; 13:275-280.
24. Özkan A, Kılıç SS, Kalkan A ve ark. Seropositivity of Epstein-Barr virus in Eastern Anatolian region of Turkey. Asian Pc J Allergy Immunol 2003;21:49-53.
25. Cohen JI. Epstein-Barr Virus Infections, Including Infectious Mononucleosis. In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson J. eds. Harrison’s Principles of Internal Medicine,
21e. McGraw-Hill Education; 2022. Accessed January 17,2024. https://accessmedicine.mhmedical.com/content.aspx?bookid=3095&sectionid=265424751
26. Zeytinoğlu A, Hekimgil M, Erensoy S ve ark. Lenfomalı hastaların dokularında Epstein-Barr virüs DNA ve RNA’sının araştırılması. Mikrobiyol Bült. 2005;39:473-481.
27. Taçyıldız N, Çavdar AO, Ertem U ve ark. Unusually high frequency of a 69-bp deletion within the carboxy terminal of the LMP-1 oncogene of Epstein-Barr virus detected in Burkitt’s lymp-
homa of Turkish children. Leukemia 1998;12:1796-1805.
28. Özdil A, Doğanay L, Demir M ve ark. Detection of Epstein-Barr virus in Hodgkin’s disease in Trakya region of Turkey; by in-situ hybridization. Tur J Haematol 2002;19:461-4.
29. Karakoyun M, Önen Ş, Baran M, Çakır M, Ömür Ecevit Ç, Kılıç M, Kantar M, Aksoylar S, Özgenç F, Aydoğdu S. Post-transplant malignancies in pediatric liver transplant recipients: Expe-
rience of two centers in Turkey. Turk J Gastroenterol. 2018;29(1):89-93. doi: 10.5152/tjg.2017.17089. PMID: 29391313; PMCID: PMC6322611.
30. Wen Y, Xu H, Han J ve ark. How Does Epstein-Barr Virus Interact With Other Microbiomes in EBV-Driven Cancers? Front Cell Infect Microbiol 2022:23;12:852066.
31. Hug M, Dorner M, Fröhlich FZ, et al. Pediatric Epstein-Barr Virus carriers with or without tonsillar enlargement may substantially contribute to spreading of the virus. J Infect Dis 2010;
202:1192-99.
32. Green M, Michaels MG. Epstein-Barr Virus infection and posttransplant lymphoproliferative disorder. Am J Transplant 2013; 13:41-54.
33. Kawada JI, Ito Y, Ohshima K ve ark. Committee for Guidelines for the Management of Chronic Active EBV Disease, Related Disorders (the MHLW Research Team in Japan). Updated guide-
lines for chronic active Epstein-Barr virus disease. Int J Hematol 2023;118(5):568-576.
34. Vouloumanou EK, Rafailidis PI, Falagas ME. Current diagnosis and management of infectious mononucleosis. Curr Opin Hematol 2012; 19:14-20.
35. Friborg JT, Melbye M. Cancer patterns in Inuit populations. Lancet Oncol. 2008 Sep;9(9):892-900.
36. Saglam A, Akyurek N, Soylemezoglu F ve ark. Epstein-Barr virus frequency in primary central nervous system lymphomas in Turkey. APMIS. 2013;121(3):232-8.
37. Levine KS, Leonard HL, Blauwendraat C ve ark. Virus exposure and neurodegenerative disease risk across national biobanks. Neuron. 2023;111(7):1086-1093.
38. Mahmood R, Mohamed K, Saeed N ve ark. The vagaries of IgM: a case report of EBV infection with concomitantly false-positive IgM for CMV, VZV, and HSV. Egypt J Intern Med 32, 14
(2020).
39. Colak M, Sarzhanova S, Yegin ZA ve ark. Determination and Role of Epstein-Barr Virus in Patients With Lymphoproliferative Disorders. Clin Lymphoma Myeloma Leuk. 2021;21(5):e488-e492.
40. Uner A, Akyurek N, Saglam A ve ark. The presence of Epstein-Barr virus (EBV) in diffuse large B-cell lymphomas (DLBCLs) in Turkey: special emphasis on ‘EBV-positive DLBCL of the
elderly’. APMIS. 2011;119(4-5):309-16.
41. Ozsan N, Cagirgan S, Saydam G ve ark. Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey. Pathol Res Pract.
2013;209(8):471-8.
42. Germi R, Lupo J, Semenova T, et al. Comparison of commercial extraction systems and PCR assays for quantification of Epstein-Barr virus DNA load in whole blood. J Clin Microbiol 2012;
50:1384-1389.
43. Ruf S, Behnke-Hall K, Gruhn B, et al. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation
or after allogeneic hematopoietic stem cell transplantation. J Clin Virol 2012; 53:186-194.
44. Buelow D, Sun Y, Tang L ve ark. Comparative Evaluation of Four Real-Time PCR Methods for the Quantitative Detection of Epstein-Barr Virus from Whole Blood Specimens. J Mol Diagn.
2016;18(4):527-34.
45. Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, Ljungman P; Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious
Diseases Working Party of the European Society of Blood and Marrow Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organization for Research and Tre-
atment of Cancer (EORTC-IDG), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Management of Epstein-Barr Virus infections and
post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.
Haematologica. 2016;101(7):803-11.
46. Kawada J, Yasuko Kamiya, Akihisa Sawada ve ark. Viral DNA Loads in Various Blood Components of Patients With Epstein-Barr Virus–Positive T-Cell/Natural Killer Cell Lymphoprolifera-
tive Diseases, The Journal of Infectious Diseases 2019: 220(8);1307–11.
47. Chakravorty S, Afzali B, Kazemian M. EBV-associated diseases: Current therapeutics and emerging technologies. Front Immunol. 2022: 27;13:1059133.